Authors

Roger Tatoud, Origena Consulting, Ferney Voltaire, France
Yves Lévy, Vaccine Research Institute, Créteil, France
Roger Le Grand, Department of Infectious Diseases Models for Innovative Therapies
Jose Alcami, Fundació de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer
Giorgio Barbareschi, European AIDS Treatment Group
Christian Brander, IRSICAIXA AIDS Research Institute
Andrea Cara, Instituto Superiore di Sanità
Behazine Combadière, Sanofi, Marcy-l'Étoile, France
François Dabis, University of Bordeaux
Sarah Fidler, Imperial College London
Tomáš Hanke
Carolina Herrera, Macon & Joan Brock Virginia Health SciencesFollow
Gunilla B. Karlsson Hedestam, Karolinska Institute
Hester Kuipers, IAVI, Amsterdam, The Netherlands
Sheena McCormack, University College London
Christiane Moog, Université de Strasbourg
Giuseppe Pantaleo, University of Lausanne
Laura Richert, University of Bordeaux
Rogier W. Sanders, Amsterdam University Medical Centers
Robin Shattock, Imperial College London
Hendrik Streeck, Institute of Virology, Bonn, Germany
Rodolphe Thiebaut, University of Bordeaux
Alexandra Trkola, Institute of Medical Virology
Klaus Üeberla, Virology Institute, Erlangen, Germany
Marit J. Van Gills, University of Amsterdam
Ralf Wagner, Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), Regensburg, Germany
Winfried Weissenhorn, Institut de Biologie Structurale (IBS), Grenoble, France
Yazdan Yazdanpanah, ANRS Emerging Infectious Diseases
Gabriella Scarlatti, IRCCS Ospedale San Raffaele, Milan, Italy
Jean Daniel Lelièvre, Henri Mondor University Hospital

ORCID

0000-0003-3701-752X (Herrera)

Document Type

Article

Publication Date

2025

DOI

10.1371/journal.pgph.0004364

Publication Title

PLOS Global Public Health

Volume

5

Issue

4

Pages

e0004364 (1-10)

Abstract

Highly effective antiretroviral-based HIV prevention plays an important role in ending the global HIV/AIDS epidemic. However, the sustainable control of the epidemic is hampered by unequal access to prevention options, including HIV testing, alongside with drug resistance and ongoing barriers to accessing sustainable HIV treatment. Therefore, an HIV vaccine, combined with effective prevention and treatment, remains an absolute necessity to control the epidemic. Yet, the recent discontinuation of four major vaccine efficacy studies is raising concerns about the future of HIV vaccine research and development globally, and particularly in the European region where funding for vaccine research and development has shrinked. This viewpoint emphasises that supporting HIV vaccine research and development at the European level remains crucial: it is not only necessary to control the epidemic, but it promotes innovation, strengthens health security, epidemic preparedness, and health sovereignty while contributing to the economies of European nations.

Rights

© 2025 Tatoud et al.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Original Publication Citation

Tatoud, R., Lévy, Y., Le Grand, R., Alcami, J., Barbareschi, G., Brander, C., Cara, A., Combadière, B., Dabis, F., Fidler, S., Hanke, T., Herrera, C., Karlsson Hedestam, G. B., Kuipers, H., McCormack, S., Moog, C., Pantaleo, G., Richert, L., Sanders, R. W.,…Lelièvre, J. D. (2025). In danger: HIV vaccine research and development in Europe. PLOS Global Public Health, 5(4), 1-10, Article e0004364. https://doi.org/10.1371/journal.pgph.0004364

pgph.0004364.s001.docx (44 kB)
Supporting Information

Share

COinS